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(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.) 1st Editorial Decision 02 November 2011
Thank you for submitting your manuscript for consideration by The EMBO Journal. After some delay caused by difficulties with the availability of willing and suitable referees at the time of submission, it has now been seen by three referees whose comments are shown below. You will see that the referees are generally positive about your work and that they would support its ultimate publication in The EMBO Journal after appropriate revision. I would thus like to invite you to prepare a revised manuscript in which you need to address the referees' criticisms in in adequate manner.
I should add that it is EMBO Journal policy to allow only a single round of revision, and acceptance of your manuscript will therefore depend on the completeness of your responses in this revised version.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Peer Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely,
Editor
The EMBO Journal
This work combines a wide range of biophysical and genetic approaches to study the structure and function of the Hsp70/Hsp90 cochaperone Sti1 in detail. Although much work has already been published on the interaction between Sti1 (Hop) and Hsp70 and Hsp90, this study provides further structural and functional information on the Hsp90-Sti1 complex. This includes data on the role of the linker regions between the Sti1 TPR domains, and the aspartic acid-proline rich DP domains, neither of which have been studied before. The work results in a better understanding of the structures of Hsp90-cochaperone complex that is formed and its functional role in the activation of client proteins.
My only criticism of the manuscript is that it contains sections the results of which have to a large degree already been established and previously published. For example, the section on "Dissection of Sti1 peptide binding" , where the affinities of the Hsp70 and 90 C-terminal peptides for the individual TPR domains are reported is very similar to earlier studies -see references in the penultimate paragraph of the Intro and also work by the Blatch group. In addition, the section on "Structural basis of the peptide specificity of the Sti1 TPR domains" reports the structures (or structural models ) of TPR:peptide complexes, several of which have already been published. It is unclear how much these sections add to the overall paper.
In summary, and despite the minor criticism, there is considerable original work presented in the paper which enhances our understanding of an enormously important but complex cellular machine.
Referee #2
This is the most comprehensive structure-function analysis of Sti1/Hop to date, nicely guided by the new structural insights that the authors provide as well. The results provide a whole series of unexpected insights such as new and more comprehensively dissected roles for several Sti1 domains. Taken altogether, the data allow new conclusions about how Hsp90 loads clients (or takes over client from Hsp70-Sti1) and about how Sti1 regulates the ATPase cycle of Hsp90. This is all nicely discussed in the paper. Once again, the Buchner lab delivers a fine piece of biochemistry and biophysics.
Minor comments:
(1) Page 7, Fig. 2 : the comparison between different TPR domains and binding peptides is interesting. However, it would be easier to follow if text and figure were a bit more explicit about whether it is the isolated TPR domains or the A-B module that are being discussed. For example, in Fig. 2D , it is not clear whether the data are from the isolated or the combined domains. If this figure does not include the A-B module, that would also clearly be nice to add.
(2) Src data (page 10): the data on v-Src are discussed but they are nowhere to be found. Although they could be mentioned as "data not shown", a In my view the HSP90 mutants used in the study of Schmid et al (figure 4) are the most convincing to suggest that it is indeed the middle domain of HSP90 that is involved in direct (core) interaction with HOP. This, rather than direct binding, may have caused the HOP-mediated conformational changes in the NBD or DD, leading to inhibition of the ATPase activity of HSP90.
Schmid et al General evaluation:
Schmid et al start to show that TPR1 binds with highest affinity to HSP70 peptides, whilst TPR2a selectively binds HSP90 peptides. TPR2b binds both with relative low affinity already maximally with the less stringent heptapeptides. Next they elegantly demonstrate (fig 1) that the HOP-mediated inhibition of the HSP90 ATPase does NOT required TPR1-DP1 and DP2 but that TRP2a-TPR2b suffice for this action, provided the linker between TRP2a andTPR2b is also included. Using crystallization, it is next shown that the linker between TPR2a en TPR2b orients the two TPR motifs in opposite directions in an S-shape allowing a bipartite binding along the HSP90 molecule. Whilst the structure of both TPR motifs are quit similar, they show how bindings to HSP70/90 peptides differs. Using a series of NMR spectroscopy data they than suggest that DP2 but not DP1 may contain a groove for ligand binding. It is subsequently shown that TRP2a and TPR2b, both individually as well as an intact fragment can (jointly) bind the HSP90 M-domain. DP2 seems not required for such a binding. Using a series of HSP90 single amino-acid mutants, it is shown that TPR2A is bound to the C-terminal end of the M-domain, whilst TPR2B is bound to the N-terminal part of the M-domain. The modeling data are also consistent with the findings that in such a complex with HSP90, TRP2B is still available to bind HSP70. To explore the functional relevance of their findings, the authors next perform complementation analyses in yeast (v-scr mediated growth arrest) and GR receptor activity in yeast that show that:
-the TPR1 is not required for GR activity -the TRP2a-TPR2b-DP2 is (almost) sufficient for activity -the DP2 that is not required for binding to HSP90, is required for activity which for the first time sheds light on the biological relevance for this motif -the DP2 activity cannot be replaced by DP1 (swap mutant) and mutations in helix 3 and 4 of DP2 disrupt this activity.
-mutations in the linker between TPR2a and TPR2B (required for HSP90 binding) also impair this activity -mutations in the presumed peptide binding site in TPR2b also impair this activity although they did not affect the formation of a HSP70-HOP-HSP90 ternary complex
Except for the two minor points (see below), I find the data in this MS convincing and I especially appreciate the functional data that are supportive of the model they present in figure 6 on the putative mechanism of HOP-mediated client transfer from HSP70 to HSP90. Here, HOP is suggested to first bind to HSP70-loaded with clients via its TPR1 domain. Next, via TRP2a binding to the C-terminal MEEVD and/or the end of the M-domain of HSP90, HOP mediates the formation of the ternary complex in which it positions it self on HSP90 (via the rigid linker and TRP2B binding to the N-terminal end of the M-domain) leading to conformational changes (described by Lee et al) that inhibit the ATPase activity of HSP90. The next step of movement of the HSP70-client towards HSP90 is still not well understood but likely relies on DP2-client affinity, the flexible linker between TPR1-DP1 and the TRP2a-TPR2b-DP2, and/or the ability of release of HSP70 from TPR1 and binding to TPR2B. This model is consistent with most of the data presented by Lee et al, except for the exact positioning of binding of HOP to HSP90.
Specific comments:
Figure 1: for completeness, it would be informative if the authors would here also include the single domain deletion mutants (e.g. delta TPR2a or delta TPR2b) as used in their GR activity experiments.
Page 10: The authors should somehow not only mention but actually present data on the complementation analysis. This section has been rewritten to address this issue. The emphasis is now on the structural basis of the peptide specificity for the TPR2B domain, which has so far not been analyzed.
Referee #2
"(1) Page 7, Fig. 2 We introduced a figure for the v-Src survival assay in the Supplementary Data (see Figure S3 ).
Referee #3
" Figure 1: We included a scheme of the different deletion constructs of Sti1 in Figure 1 .
"Page 10: The authors should somehow not only mention but actually present data on the complementation analysis."
We introduced a figure for the v-Src survival assay in the Supplementary Data (see Figure S3 ).
2nd Editorial Decision 28 November 2011
Thank you for sending us your revised manuscript. I have now had a chance to look at it in depth, and you will be pleased to learn that you have addressed all criticisms in a satisfactory manner and that the paper will be publishable in The EMBO Journal.
Prior to formal acceptance, there are a number of editorial issues that need further attention.
* Please reformat the references section to EMBO Journal format (no numbering, alphabetical order, for details please refer to our author instructions) * Please add a conflict of interest statement to the main body of the manuscript text after the author contribution section.
* Please add the PDB accession numbers also to the acknowledgements section in the main body of the manuscript text.
* Please include the statistical details including the number of independent repeats into the legends of table 1 and figure 1.
Thank you very much again for considering our journal for publication of your work. We are looking forward to the final version of the manuscript.
